Literature DB >> 16135025

Combining multiple comparisons and modeling techniques in dose-response studies.

F Bretz1, J C Pinheiro, M Branson.   

Abstract

The analysis of data from dose-response studies has long been divided according to two major strategies: multiple comparison procedures and model-based approaches. Model-based approaches assume a functional relationship between the response and the dose, taken as a quantitative factor, according to a prespecified parametric model. The fitted model is then used to estimate an adequate dose to achieve a desired response but the validity of its conclusions will highly depend on the correct choice of the a priori unknown dose-response model. Multiple comparison procedures regard the dose as a qualitative factor and make very few, if any, assumptions about the underlying dose-response model. The primary goal is often to identify the minimum effective dose that is statistically significant and produces a relevant biological effect. One approach is to evaluate the significance of contrasts between different dose levels, while preserving the family-wise error rate. Such procedures are relatively robust but inference is confined to the selection of the target dose among the dose levels under investigation. We describe a unified strategy to the analysis of data from dose-response studies which combines multiple comparison and modeling techniques. We assume the existence of several candidate parametric models and use multiple comparison techniques to choose the one most likely to represent the true underlying dose-response curve, while preserving the family-wise error rate. The selected model is then used to provide inference on adequate doses.

Mesh:

Year:  2005        PMID: 16135025     DOI: 10.1111/j.1541-0420.2005.00344.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  50 in total

1.  An example of optimal phase II design for exposure response modelling.

Authors:  Alan Maloney; Marloes Schaddelee; Jan Freijer; Walter Krauwinkel; Marcel van Gelderen; Philippe Jacqmin; Ulrika S H Simonsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-09-25       Impact factor: 2.745

2.  A decision-theoretic phase I-II design for ordinal outcomes in two cycles.

Authors:  Juhee Lee; Peter F Thall; Yuan Ji; Peter Müller
Journal:  Biostatistics       Date:  2015-11-09       Impact factor: 5.899

3.  Adaptive dose finding based on t-statistic for dose-response trials.

Authors:  Anastasia Ivanova; James A Bolognese; Inna Perevozskaya
Journal:  Stat Med       Date:  2008-05-10       Impact factor: 2.373

4.  Statistical Methods for Selecting Maximum Effective Dose and Evaluating Treatment Effect When Dose - Response is Monotonic.

Authors:  Maiying Kong; Shesh N Rai; Roberto Bolli
Journal:  Stat Biopharm Res       Date:  2014-01-02       Impact factor: 1.452

5.  Optimal designs for comparing curves.

Authors:  Holger Dette; Kirsten Schorning
Journal:  Ann Stat       Date:  2016-04-11       Impact factor: 4.028

6.  Practical considerations for optimal designs in clinical dose finding studies.

Authors:  Frank Bretz; Holger Dette; Jose C Pinheiro
Journal:  Stat Med       Date:  2010-03-30       Impact factor: 2.373

7.  Comparison of Model Averaging and Model Selection in Dose Finding Trials Analyzed by Nonlinear Mixed Effect Models.

Authors:  Simon Buatois; Sebastian Ueckert; Nicolas Frey; Sylvie Retout; France Mentré
Journal:  AAPS J       Date:  2018-03-29       Impact factor: 4.009

8.  Adaptive Optimal Designs for Dose-Finding Studies with Time-to-Event Outcomes.

Authors:  Yevgen Ryeznik; Oleksandr Sverdlov; Andrew C Hooker
Journal:  AAPS J       Date:  2017-12-28       Impact factor: 4.009

9.  Fevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids.

Authors:  Eric D Bateman; Alfredo G Guerreros; Florian Brockhaus; Björn Holzhauer; Abhijit Pethe; Richard A Kay; Robert G Townley
Journal:  Eur Respir J       Date:  2017-08-24       Impact factor: 16.671

10.  The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy.

Authors:  Julio Rosenstock; Salomon Banarer; Vivian A Fonseca; Silvio E Inzucchi; William Sun; Wenqing Yao; Gregory Hollis; Robert Flores; Richard Levy; William V Williams; Jonathan R Seckl; Reid Huber
Journal:  Diabetes Care       Date:  2010-04-22       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.